View ValuationEnimmune 将来の成長Future 基準チェック /06現在、 Enimmuneの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長29.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 09Full year 2025 earnings released: NT$2.28 loss per share (vs NT$2.20 loss in FY 2024)Full year 2025 results: NT$2.28 loss per share (further deteriorated from NT$2.20 loss in FY 2024). Revenue: NT$48.2m (up 21% from FY 2024). Net loss: NT$164.3m (loss widened 4.3% from FY 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.お知らせ • Mar 10Enimmune Corporation, Annual General Meeting, Jun 09, 2026Enimmune Corporation, Annual General Meeting, Jun 09, 2026. Location: no,328, chun fu rd., pei tun district, taichung city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$42m revenue, or US$1.3m). Market cap is less than US$100m (NT$1.36b market cap, or US$43.3m).New Risk • Aug 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$42m revenue, or US$1.4m). Market cap is less than US$100m (NT$1.70b market cap, or US$55.5m).お知らせ • Mar 12Enimmune corporation, Annual General Meeting, Jun 17, 2025Enimmune corporation, Annual General Meeting, Jun 17, 2025, at 09:00 Taipei Standard Time. Location: no,328, chun fu rd., pei tun district, taichung city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.5% average weekly change). Revenue is less than US$5m (NT$51m revenue, or US$1.5m). Market cap is less than US$100m (NT$1.84b market cap, or US$55.9m).New Risk • Feb 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (NT$51m revenue, or US$1.5m). Market cap is less than US$100m (NT$1.89b market cap, or US$57.2m).New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Revenue is less than US$5m (NT$51m revenue, or US$1.6m). Market cap is less than US$100m (NT$2.52b market cap, or US$78.7m).Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.58 loss per share (vs NT$0.59 loss in 2Q 2023)Second quarter 2024 results: NT$0.58 loss per share. Net loss: NT$39.6m (loss widened 2.0% from 2Q 2023).New Risk • Jul 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (NT$43m revenue, or US$1.3m). Market cap is less than US$100m (NT$2.89b market cap, or US$88.2m).お知らせ • Mar 22Enimmune corporation, Annual General Meeting, Jun 12, 2024Enimmune corporation, Annual General Meeting, Jun 12, 2024.Reported Earnings • Mar 14Full year 2023 earnings released: NT$3.40 loss per share (vs NT$3.88 loss in FY 2022)Full year 2023 results: NT$3.40 loss per share (improved from NT$3.88 loss in FY 2022). Net loss: NT$223.7m (loss narrowed 9.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$109m revenue, or US$3.5m). Market cap is less than US$100m (NT$2.45b market cap, or US$77.6m).New Risk • Aug 13New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: NT$109m (US$3.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$109m revenue, or US$3.4m). Market cap is less than US$100m (NT$2.85b market cap, or US$89.3m).New Risk • Jul 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$3.13b market cap, or US$99.7m).Reported Earnings • Apr 23Full year 2022 earnings released: NT$3.88 loss per share (vs NT$0.79 loss in FY 2021)Full year 2022 results: NT$3.88 loss per share (further deteriorated from NT$0.79 loss in FY 2021). Revenue: NT$188.4m (up 72% from FY 2021). Net loss: NT$248.0m (loss widened 425% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • May 02Full year 2021 earnings released: NT$0.79 loss per share (vs NT$1.40 loss in FY 2020)Full year 2021 results: NT$0.79 loss per share (up from NT$1.40 loss in FY 2020). Revenue: NT$109.8m (up 380% from FY 2020). Net loss: NT$47.2m (loss narrowed 37% from FY 2020). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 35% per year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 02Enimmune corporation, Annual General Meeting, Jun 21, 2022Enimmune corporation, Annual General Meeting, Jun 21, 2022.Reported Earnings • Apr 25Full year 2020 earnings released: NT$1.40 loss per share (vs NT$1.29 loss in FY 2019)Full year 2020 results: Net loss: NT$74.5m (loss widened 31% from FY 2019).Is New 90 Day High Low • Feb 20New 90-day high: NT$51.70The company is up 12% from its price of NT$46.00 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period.Is New 90 Day High Low • Dec 05New 90-day low: NT$42.75The company is down 32% from its price of NT$62.60 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period.Is New 90 Day High Low • Nov 12New 90-day low: NT$43.10The company is down 32% from its price of NT$63.50 on 14 August 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Sep 30New 90-day low: NT$52.10The company is down 43% from its price of NT$91.00 on 02 July 2020. The Taiwanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Enimmune は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6564 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202548-164-147-143N/A9/30/202545-165-158-155N/A6/30/202542-165-168-167N/A3/31/202541-161-156-155N/A12/31/202440-158-144-144N/A9/30/202445-194-147-146N/A6/30/202451-231-149-149N/A3/31/202447-228-144-143N/A12/31/202343-224-138-138N/A9/30/202376-197-144-144N/A6/30/2023109-170-150-149N/A3/31/2023149-209-175-175N/A12/31/2022188-248-201-201N/A9/30/2022170-219-182-181N/A6/30/2022151-190-162-162N/A3/31/2022131-118-119-117N/A12/31/2021110-47-75-72N/A9/30/202191-53-99-93N/A6/30/202173-60-122-115N/A3/31/202148-67-117-111N/A12/31/202023-74-112-107N/A9/30/202012-67-83-80N/A6/30/20201-60-53-53N/A3/31/20202-59-57-57N/A12/31/20192-57-60-60N/A9/30/20192-76N/A-71N/A6/30/20191-95N/A-81N/A3/31/20191-98N/A-84N/A12/31/20181-101N/A-86N/A9/30/20182-77N/A-77N/A6/30/20182-54N/A-68N/A3/31/20182-44N/A-57N/A12/31/20172-34N/A-47N/A9/30/20172-31N/A-58N/A6/30/20172-28N/A-70N/A3/31/20172-47N/A-71N/A12/31/20162-66N/A-71N/A9/30/20162-67N/A-51N/A6/30/20162-68N/A-30N/A3/31/20161-56N/A-37N/A12/31/20151-43N/A-43N/A9/30/20150-37N/A-37N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6564の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6564の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6564の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6564の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6564の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6564の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/03 04:42終値2026/07/03 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enimmune Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 09Full year 2025 earnings released: NT$2.28 loss per share (vs NT$2.20 loss in FY 2024)Full year 2025 results: NT$2.28 loss per share (further deteriorated from NT$2.20 loss in FY 2024). Revenue: NT$48.2m (up 21% from FY 2024). Net loss: NT$164.3m (loss widened 4.3% from FY 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
お知らせ • Mar 10Enimmune Corporation, Annual General Meeting, Jun 09, 2026Enimmune Corporation, Annual General Meeting, Jun 09, 2026. Location: no,328, chun fu rd., pei tun district, taichung city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 22% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$42m revenue, or US$1.3m). Market cap is less than US$100m (NT$1.36b market cap, or US$43.3m).
New Risk • Aug 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.8% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$42m revenue, or US$1.4m). Market cap is less than US$100m (NT$1.70b market cap, or US$55.5m).
お知らせ • Mar 12Enimmune corporation, Annual General Meeting, Jun 17, 2025Enimmune corporation, Annual General Meeting, Jun 17, 2025, at 09:00 Taipei Standard Time. Location: no,328, chun fu rd., pei tun district, taichung city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (6.5% average weekly change). Revenue is less than US$5m (NT$51m revenue, or US$1.5m). Market cap is less than US$100m (NT$1.84b market cap, or US$55.9m).
New Risk • Feb 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (NT$51m revenue, or US$1.5m). Market cap is less than US$100m (NT$1.89b market cap, or US$57.2m).
New Risk • Sep 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Revenue is less than US$5m (NT$51m revenue, or US$1.6m). Market cap is less than US$100m (NT$2.52b market cap, or US$78.7m).
Reported Earnings • Aug 18Second quarter 2024 earnings released: NT$0.58 loss per share (vs NT$0.59 loss in 2Q 2023)Second quarter 2024 results: NT$0.58 loss per share. Net loss: NT$39.6m (loss widened 2.0% from 2Q 2023).
New Risk • Jul 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (NT$43m revenue, or US$1.3m). Market cap is less than US$100m (NT$2.89b market cap, or US$88.2m).
お知らせ • Mar 22Enimmune corporation, Annual General Meeting, Jun 12, 2024Enimmune corporation, Annual General Meeting, Jun 12, 2024.
Reported Earnings • Mar 14Full year 2023 earnings released: NT$3.40 loss per share (vs NT$3.88 loss in FY 2022)Full year 2023 results: NT$3.40 loss per share (improved from NT$3.88 loss in FY 2022). Net loss: NT$223.7m (loss narrowed 9.8% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (NT$109m revenue, or US$3.5m). Market cap is less than US$100m (NT$2.45b market cap, or US$77.6m).
New Risk • Aug 13New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: NT$109m (US$3.4m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risks Revenue is less than US$5m (NT$109m revenue, or US$3.4m). Market cap is less than US$100m (NT$2.85b market cap, or US$89.3m).
New Risk • Jul 23New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.13b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$3.13b market cap, or US$99.7m).
Reported Earnings • Apr 23Full year 2022 earnings released: NT$3.88 loss per share (vs NT$0.79 loss in FY 2021)Full year 2022 results: NT$3.88 loss per share (further deteriorated from NT$0.79 loss in FY 2021). Revenue: NT$188.4m (up 72% from FY 2021). Net loss: NT$248.0m (loss widened 425% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • May 02Full year 2021 earnings released: NT$0.79 loss per share (vs NT$1.40 loss in FY 2020)Full year 2021 results: NT$0.79 loss per share (up from NT$1.40 loss in FY 2020). Revenue: NT$109.8m (up 380% from FY 2020). Net loss: NT$47.2m (loss narrowed 37% from FY 2020). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 35% per year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 02Enimmune corporation, Annual General Meeting, Jun 21, 2022Enimmune corporation, Annual General Meeting, Jun 21, 2022.
Reported Earnings • Apr 25Full year 2020 earnings released: NT$1.40 loss per share (vs NT$1.29 loss in FY 2019)Full year 2020 results: Net loss: NT$74.5m (loss widened 31% from FY 2019).
Is New 90 Day High Low • Feb 20New 90-day high: NT$51.70The company is up 12% from its price of NT$46.00 on 20 November 2020. The Taiwanese market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period.
Is New 90 Day High Low • Dec 05New 90-day low: NT$42.75The company is down 32% from its price of NT$62.60 on 04 September 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Nov 12New 90-day low: NT$43.10The company is down 32% from its price of NT$63.50 on 14 August 2020. The Taiwanese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Sep 30New 90-day low: NT$52.10The company is down 43% from its price of NT$91.00 on 02 July 2020. The Taiwanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.